PL7737 / Palatin Technologies - LARVOL DELTA

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency (PRNewswire) - "IND submission planned for 4Q25...Palatin Technologies, Inc...announced the US Food & Drug Administration (FDA) has granted 'orphan drug' designation to PL7737, an oral treatment that activates the melanocortin-4 receptor, for leptin receptor (LEPR) deficiency, including obesity caused by this condition...'We are also exploring PL7737 for hypothalamic obesity and plan to begin a Phase 1 SAD/MAD study in late 2025.'"

IND • New P1 trial • Orphan drug • Obesity